MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV) in a research report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Up 14.5 %

Shares of MNOV opened at $1.50 on Tuesday. The stock has a 50 day moving average price of $1.31 and a 200 day moving average price of $1.36. The company has a market capitalization of $73.57 million, a price-to-earnings ratio of -8.82 and a beta of 0.72. MediciNova has a 52-week low of $1.12 and a 52-week high of $2.49.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.